论文部分内容阅读
目的：恶性脑胶质瘤细胞对化疗药物表现出的耐药性是临床化疗失败的主要原因之一，检测脑胶质瘤中多药耐药基因（ＭＤＲ１）的表达，可以为临床医师选择制定化疗方案提供理论依据。方法：作者采用逆转录－多聚酶链式反应（ＲＴ－ＰＣＲ）技术，建立了临床脑胶质瘤ＭＤＲ１－ｍＲＮＡ表达的检测方法。结果：检测了３２例脑胶质瘤标本，发现初治原发性脑胶质瘤中ＭＤＲ１基因表达阳性率为３７．５％（１２／３２），并与肿瘤细胞的分化程度相关。结论：多药耐药现象在部分原发性脑胶质瘤中先天存在。ＲＴ－ＰＣＲ方法检测临床脑胶质瘤标本时具有相对敏感、特异、方便、快速、结果可靠等优点
OBJECTIVE: The manifestation of resistance to chemotherapeutic drugs in malignant glioma cells is one of the major causes of clinical chemotherapy failure. Detection of the expression of multidrug resistance gene (MDR1) in glioma can be selected by clinicians. The chemotherapy protocol provides a theoretical basis. Methods: The authors used reverse transcription-polymerase chain reaction (RT-PCR) technology to establish a method for the detection of MDR1-mRNA expression in clinical gliomas. RESULTS: Thirty-two cases of glioma were detected. The positive rate of MDR1 gene expression in the primary primary glioma was 37.5% (12/32), which was related to the degree of tumor cell differentiation. Conclusion: The phenomenon of multidrug resistance exists in some primary gliomas. The RT-PCR method has the advantages of relative sensitivity, specificity, convenience, rapidity, and reliable results when detecting clinical glioma specimens.